CDKN1A and breast carcinoma: Hence, the presence of wild-type p53 appears to suppress the detrimental effects of high c-MYC/AP4 levels in breast carcinomas, possibly via activation of p21 and consequently, DREAM-mediated repression of cell cycle regulatory genes.